1. Australia Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Imagion Biosystems Ltd.

Imagion Biosystems Ltd.

0.01
AUD
0.00
(0.00%)
-0.02EPS
12.19MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
- -
- -
0.03
0.05
0.01
0.01
0.02
0.04
0.03
- -
Basic EPS, GAAP
- -
-1.7
-1.42
-0.38
-0.29
-0.23
-0.35
-0.43
-0.05
-0.02
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.11
1.14
0.45
0.22
0.52
0.47
0.17
-0.14
-0.01
- -
Tangible Book Value per Share
0.11
1.14
0.45
0.22
0.52
0.47
0.17
-0.14
-0.01
- -
Basic Weighted Avg Shares
103
5
6
9
19
26
28
30
45
277
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
1
1
- -
Operating Margin (%)
- -
-35,706.71
-4,677.93
-1,331.29
-3,767.37
-3,709.29
-2,583.06
-1,122.52
-194.15
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
1
1
- -
- -
Net Income, GAAP
- -
-8
-8
-3
-5
-6
-10
-13
-2
-4
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
-38,775.26
-4,355.62
-835.46
-2,607.47
-2,587.21
-2,071.53
-955.43
-178.15
- -
Working Capital
11
13
4
2
13
13
3
-6
-2
-2
LT Debt
- -
- -
- -
1
- -
- -
4
4
- -
- -
Total Equity
12
7
4
3
13
13
5
-5
-2
-2
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-83.62
-154.13
-100.33
-67.53
-45.96
-109.07
- -
- -
- -

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-63.71%
-5.3%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
26.53%
108.49%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1
2024
- -
- -
1
2025
- -
- -
- -

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.43
2024
- -
- -
-0.05
2025
- -
- -
-0.02

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Robert Romeo Proulx
Full Time Employees
11
Sector
Health technology
Industry
Medical specialties
Address
Suite 2 South Melbourne VIC Australia 3000
IPO Date
Jun 22, 2017
Website
imagionbiosystems.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Imagion Biosystems Limited (ASX:IBX) develops non-radioactive molecular magnetic resonance imaging (MRI) technologies for the early detection and staging of cancer using superparamagnetic iron oxide nanoparticles (SPIONs) linked to cancer-specific biomarkers; its lead product, MagSense HER2 imaging agent, targets HER2-positive breast cancer to identify nodal metastases as small as 1-2 mm; additional MagSense agents target prostate-specific membrane antigen (PSMA) for prostate cancer and folate receptors for ovarian cancer; the company also pursues PrecisionMRX nanoparticles for magnetic relaxometry and other biomedical applications. Founded in 2016 and headquartered in South Melbourne, Australia, with operations in San Diego, California, Imagion Biosystems focuses on nanotechnology, biotechnology, and cancer diagnostics segments, serving clinicians and healthcare providers in the oncology market primarily in the United States and Australia. Recent developments include completion of Phase I clinical trials for MagSense HER2, positive U.S. FDA feedback supporting an Investigational New Drug (IND) application planned for Q4 2025 to initiate a Phase II trial in early 2026, manufacturing of a new clinical batch of the HER2 agent, a $3.5 million capital raise in August-September 2025 led by CPS Capital Group to fund the IND and trial, a collaboration with Wayne State University for optimized MRI protocols adding to its existing Siemens Healthineers partnership, and appointment of Dr. Nina Webster as non-executive director in September 2025.

Company News

Company News APIChatGPT

  • gurufocus.com

    Imagion Biosystems Secures AU$3.75M in Capital Raise Following FDA Clearance of Phase 2 Clinical Trial

  • gurufocus.com

    Imagion Biosystems' IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review